The Seasonal Vaccines Market Will Experience Solid Growth from 2015–2025
The global seasonal influenza vaccine market, which for the purposes of this report comprises the 7MM (7MM – The US, France, Germany, Italy, Spain, UK, and Japan), generated about $3.1 billion in sales in 2015. GlobalData expects this market to experience solid growth, reaching sales of $4.3 billion by 2025 at a compound annual growth rate (CAGR) of 3.3%. The majority of this growth will occur in the 5EU, driven by the uptake of egg-based quadrivalent vaccines as the older and less expensive trivalent vaccines are gradually phased out. The seasonal influenza vaccines market in the 5EU is expected to grow at a CAGR of 5.5%, reaching sales of $1.0 billion by 2025. GlobalData estimates sales in the US to grow moderately at a CAGR of 3.5% during the next 10 years, reaching $2.6 billion by 2025, while Japan will experience less pronounced growth, posting a CAGR of 0.3%.
Key highlights from the report:
- Pharma Giants Flex their Marketing and Manufacturing Capabilities to Expand their Market Shares
- Improved Public Awareness Remains a Key Unmet Need in the Seasonal Influenza Vaccines Space
- National Immunization Schedules Shift Toward Vaccinating Children Against Seasonal Influenza, Generating an Opportunity for Market Penetration
Quadrivalent Vaccines and Cell Culture-Based Manufacturing Technology Will Energize the Seasonal Influenza Vaccines Market
PharmaPoint: Seasonal Influenza Vaccines – Global Drug Forecast and Market Analysis to 2025
Report Information:
Price: $10,995 (Single User License)
Published: Nov 2016
Publisher: GlobalData
Report Format: electronic pdf